Statement of Larry Corey, MD on the Success of the CAPRISA 004 Microbicide Trial
VIENNA, July 19 Today's news of a microbicide that significantly reduced HIV infection is an exciting step forward in the fight against HIV. Equally exciting is the news that the microbicide also reduced the rate of infection of the herpes virus (HSV2), as we know that HSV2 infection increases the risk of acquiring HIV.
This study, CAPRISA 004, is a testament to the support and engagement of the women of Durban, South Africa and the commitment of Drs. Salim and Quarraisha Abdool Karim who led the investigative team that conducted the study.
These results also reinforce the importance of trials in humans to investigate the effect of biomedical interventions for HIV and indicate the beginning successes that new technologies are bringing to the fight against HIV.
Dr. Corey is the Co-Director of the Vaccine and Infectious Disease Division at Fred Hutchinson Cancer Research Center, and the Principal Investigator of the HIV Vaccine Trials Network. The Network is supported through a cooperative agreement with the National Institute of Allergy and Infectious Diseases.
For more information: Sarah B. Alexander +1-206-910-3801
SOURCE HIV Vaccine Trials Network
You May Also Like